• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar

McCarter & English Logo

  • People
  • Services
  • Insights
  • Our Firm
    • Leadership Team
    • Social Justice
    • Diversity & Inclusion
    • Pro Bono
    • Client Service Values
  • Join Us
    • Lawyers
    • Summer Associates
    • Patent Professionals
    • Professional Staff
    • Job Openings
  • Locations
    • Boston
    • Philadelphia
    • East Brunswick
    • Indianapolis
    • Stamford
    • Hartford
    • Trenton
    • Miami
    • Washington, DC
    • New York
    • Wilmington
    • Newark
  • Share

Share

Browse Alphabetically:

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
  • All
Bankruptcy, Restructuring & Litigation
Blockchain, Smart Contracts & Digital Currencies
Business Litigation
Cannabis
Coronavirus Resource Center
Corporate
Crisis Management
Cybersecurity & Data Privacy
Delaware Corporate, LLC & Partnership Law
Design, Fashion & Luxury
E-Discovery & Records Management
Energy & Utilities
Environment & Energy
Financial Institutions
Food & Beverage
Government Affairs
Government Contracts & Global Trade
Government Investigations & White Collar Defense
Healthcare
Immigration
Impact Investing
Insurance Recovery, Litigation & Counseling
Intellectual Property
Labor & Employment
Life Sciences
Manufacturing
Products Liability, Mass Torts & Consumer Class Actions
Proptech
Public Finance
Real Estate
Renewable Energy
Sports & Entertainment
Tax & Employee Benefits
Technology Transactions
Transportation, Logistics & Supply Chain Management
Trusts, Estates & Private Clients
Venture Capital & Emerging Growth Companies
  • Broadcasts
  • Events
  • News
  • Publications
  • View All Insights
Search By:
Michael J. DeGrazia, PhD
Alternate image for Michael J. DeGrazia, PhD

Michael J. DeGrazia, PhD

Partner

617.449.6585
Boston
mdegrazia@mccarter.com

A skilled patent strategist, pharmaceutical and biotechnology clients value Michael's chemistry training.

Dr. Michael DeGrazia focuses his patent practice on chemical, pharmaceutical, and biotechnologies, with particular emphasis on small molecule drugs. Michael assists clients in the protection and development of their IP assets through the drafting, filing, and prosecution of U.S. and foreign patent applications; global portfolio strategy and management; freedom-to operate (FTO) assessments; patentability and infringement analyses; competitive landscape investigations; patent issues related to licensing, acquisition, and financing such as initial public offerings (IPO); and strategic counseling.

Michael is well versed in life cycle management and patent term extension. His technical experience most notably includes new chemical entities, compositions/formulations, dispersions, polymorphs, processes, patient stratifications, new medical uses, and clinical trial data protection/inclusion.

In addition to counseling and prosecution, he also has experience in patent litigation, in particular Abbreviated New Drug Application (ANDA) cases arising under the Hatch-Waxman Act and post-grant proceedings. Michael’s clients include small and large companies, academic institutions, and individual inventors. Their technologies span from investigatory and those undergoing clinical review to post-market approval and billion-dollar biotech and molecular drug products.

Michael earned his PhD in organic chemistry from the Penn State University where he studied the synthesis of fluorescently labeled small molecules for high-throughput screening and control of intracellular pathways. Prior to graduate work, he also investigated new coupling routes for modification of the anticancer drug paclitaxel (Taxol®).

Representative Matters

Constellation Pharmaceuticals—IP management and acquisition for 1.7 billion

Developed and managed Intellectual Property portfolio for Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) and participated in the diligence and strategic efforts leading to the acquisition agreement with MorphoSys AG (FSE: MOR; NASDAQ: MOR) (“MorphoSys”). The 1.7 billion dollar deal is funded by a second deal between MorphoSys (ticker: MOR) and Royalty Pharma (RPRX), which specializes in acquiring royalty rights from drug companies. Constellation’s two lead product candidates, pelabresib (CPI-0610), a BET inhibitor, and CPI-0209, a second-generation EZH2 inhibitor, are in mid- to late-stage clinical trials, and have broad therapeutic potential to offer meaningful benefits to patients with various hematological and solid tumors.

Rodin Therapeutics—Patent portfolio strategy and due diligence in 950 million dollar sale

Responsible for the patent portfolio drafting and filing strategy for Rodin Therapeutics Inc, and handled IP negotiation and diligence matters relating to Rodin’s acquisition by Alkermes plc (Nasdaq: ALKS). Rodin focuses on developing small molecule therapeutics for synaptopathies, which are diseases of the central nervous system related to a dysfunction of synapses.

Highlights

Recognitions

Recognition image 10959
Massachusetts Rising Star, Super Lawyers, 2018–2021
Recognition image 10997
Oral Advocate and Distinguished Brief Award, Suffolk Law School
Recognition image 10997
Research award for accomplishments in organic chemistry, Penn State University
Recognition image 10997
Dan H. Waugh Memorial Teaching Award, Penn State University
Recognition image 10997
Geiger Fellowship, Penn State University
Recognition image 10997
Louis A. Reber Memorial Research Award, Penn State University
Recognition image 10997
American Institute of Chemists Award, University of the Sciences
Ranking Disclaimers: No aspect of this advertisement has been approved by the Supreme Court of New Jersey. For SuperLawyers methodology, see https://www.superlawyers.com/about/selection_process.html.

sidebar

pdfemail

Services

Intellectual Property
Patents
Life Sciences

Education

Suffolk University Law School JD, 2013
Pennsylvania State University PhD Chemistry, 2008
University of the Sciences in Philadelphia BS Chemistry, magna cum laude, 2001
Middlesex County College AS Biology, 1999

Bar Admissions

Massachusetts
U.S. Patent & Trademark Office

Memberships & Certifications

Boston Patent Law Association
Co-Chair of New Lawyers, Law Students & Technology Specialists Committee

American Intellectual Property Law Association (AIPLA)

American Chemical Society (ACS)

Family Law Project for Battered Women
Pro Bono Attorney

Victim Rights Law Center (VRLC)
Pro Bono Attorney

Kids in Need of Defense (KIND)
Pro Bono Attorney

Insights Awards Top Stars
News
Attorneys Who Moved up the Firm Ranks in Q2
Law360
8.9.2018
Media item displaying Biotech Bootcamp Weekend
Events|Speaking Engagement
Biotech Bootcamp Weekend
Suffolk University & Ventac Partners
July 13-15, 2018
Insights Speaking Seminar
Events|Speaking Engagement
Introduction to Intellectual Property
Boston University Questrom School of Business
5.2.2018
Insights Awards Stars
News|Press
McCarter & English Promotes 8 to Partnership in 5 Offices, 7 Practice Groups
McCarter Press Release
4.1.2018
McCarter & English, LLP
Copyright © 2022 McCarter & English, LLP. All Rights Reserved.
  • Login
  • Attorney Advertising
  • Privacy
  • Awards Methodology
  • Contact
  • Subscribe
  • Sitemap

The McCarter & English, LLP website is for informational purposes only. We do not provide legal advice on this website. We can provide legal advice only to our clients in specific inquiries that they address to us. If you are interested in becoming a client, please contact us, but do not send any information about your specific legal question. We cannot serve as your lawyers until we establish an attorney-client relationship, which can occur only after we follow procedures within our firm and after we agree to the terms of the representation.

Accept Cancel